{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:14:35Z","timestamp":1790266475455,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/labmed\/lmx072","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T11:11:33Z","timestamp":1505387493000},"page":"25-34","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms"],"prefix":"10.1093","volume":"49","author":[{"given":"Negin","family":"Farzamikia","sequence":"first","affiliation":[{"name":"Department of Biology, East Azerbaijan Science and Research Branch, Islamic Azad University, Tabriz, Iran"},{"name":"Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Sakhinia","sequence":"additional","affiliation":[{"name":"Tuberculosis and Lung Disease Research Center, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran"},{"name":"Department of Medical Genetic, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Afrasiabirad","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Madani Heart Hospital, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11239-013-0940-x","article-title":"The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery","volume":"37","author":"Tatarunas","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0002","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejcts.2006.12.017","article-title":"Antithrombotic therapy following bioprosthetic aortic valve replacement","volume":"31","author":"Nowell","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin","volume":"105","author":"D\u2019Andrea","year":"2005","journal-title":"Blood"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ajhg.2007.10.002","article-title":"Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations","volume":"82","author":"Scott","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"7","key":"key\n\t\t\t\t20180622062738_CIT0005","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"issue":"13","key":"key\n\t\t\t\t20180622062738_CIT0006","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/sj.tpj.6500182","article-title":"Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin","volume":"3","author":"Takahashi","year":"2003","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0008","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/clpt.2011.269","article-title":"Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism","volume":"91","author":"Liu","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.gene.2014.12.068","article-title":"Genotype frequencies of VKORC1 and CYP2C9 in native and Mestizo populations from Mexico, potential impact for coumarin dosing","volume":"558","author":"Villegas-Torres","year":"2015","journal-title":"Gene"},{"issue":"1","key":"key\n\t\t\t\t20180622062738_CIT0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3121\/cmr.2007.724","article-title":"Evaluation of genetic factors for warfarin dose prediction","volume":"5","author":"Caldwell","year":"2007","journal-title":"Clin Med Res"},{"key":"key\n\t\t\t\t20180622062738_CIT0011","first-page":"34","article-title":"Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response","volume":"60","author":"Shalia","year":"2012","journal-title":"J Assoc Physicians India"},{"issue":"1-3","key":"key\n\t\t\t\t20180622062738_CIT0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2013.04.006","article-title":"Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population","volume":"710","author":"Gaikwad","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.thromres.2008.11.011","article-title":"Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients","volume":"124","author":"Yoshizawa","year":"2009","journal-title":"Thromb Res"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0014","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.thromres.2009.10.017","article-title":"Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement\u2014a systematic review and meta analysis","volume":"125","author":"Yang","year":"2010","journal-title":"Thromb Res"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.thromres.2015.01.029","article-title":"Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis","volume":"135","author":"Sun","year":"2015","journal-title":"Thromb Res"},{"issue":"22","key":"key\n\t\t\t\t20180622062738_CIT0016","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"key\n\t\t\t\t20180622062738_CIT0017","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0018","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"key\n\t\t\t\t20180622062738_CIT0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1472-8206.2004.00307.x","article-title":"CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population","volume":"19","author":"Jose","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t20180622062738_CIT0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-9560-6-7","article-title":"Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction","volume":"6","author":"Haug","year":"2008","journal-title":"Thromb J"},{"issue":"1","key":"key\n\t\t\t\t20180622062738_CIT0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00228-007-0385-2","article-title":"CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients","volume":"64","author":"Lima","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"key\n\t\t\t\t20180622062738_CIT0022","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clinbiochem.2006.01.023","article-title":"Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort","volume":"39","author":"Moridani","year":"2006","journal-title":"Clin Biochem"},{"issue":"4","key":"key\n\t\t\t\t20180622062738_CIT0023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2012.09150.x","article-title":"Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates","volume":"158","author":"Lund","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"key\n\t\t\t\t20180622062738_CIT0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2009.178","article-title":"Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients","volume":"87","author":"Pautas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"key\n\t\t\t\t20180622062738_CIT0026","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00228-008-0507-5","article-title":"VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients","volume":"64","author":"Oner Ozgon","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t20180622062738_CIT0027","first-page":"557","article-title":"Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy","volume":"32","author":"Samardzija","year":"2008","journal-title":"Coll Antropol"},{"issue":"6","key":"key\n\t\t\t\t20180622062738_CIT0028","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.clinthera.2010.06.010","article-title":"The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran","volume":"32","author":"Namazi","year":"2010","journal-title":"Clin Ther"},{"issue":"11","key":"key\n\t\t\t\t20180622062738_CIT0029","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2217\/14622416.8.11.1545","article-title":"Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians","volume":"8","author":"Borgiani","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"6","key":"key\n\t\t\t\t20180622062738_CIT0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.2008.166","article-title":"Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients","volume":"84","author":"Perini","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"key\n\t\t\t\t20180622062738_CIT0031","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients","volume":"63","author":"Miao","year":"2007","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/labmed\/article-pdf\/49\/1\/25\/25076871\/lmx072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T13:14:23Z","timestamp":1570108463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/49\/1\/25\/4653055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,11,22]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmx072","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,11,22]]}}}